Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa

Article Abstract:

The predictive strengths of CD4 cell count, HIV RNA level and the cost effective markers blood hemoglobin (HB), total lymphocyte count (TLC), body mass index (BMI) and clinical evaluation by classification into Centers for Disease Control and Prevention (CDC) category in a longitudinal cohort set in rural Zimbabwe are investigated. The results have shown HIV RNA level and CD4 cell count to predict mortality with prognostic capabilities that are similar to high-income countries.

Author: Gerstoft, Jan, Ullum, Henrik, Erikstrup, Christian, Kallestrup, Per, Zinyama, Rutendo, Gomo, Exnevia, Mudenge, Boniface
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2007
Africa, Reports, Patient outcomes, Measurement, Prevention, CD4 lymphocytes, Rural health, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy

Article Abstract:

The high plasma level of interleukin-18 (IL-18) in HIV infected patients and the association of IL-18 with fat mass and fat distribution is studied, by comparing HIV-infected men with lipodystrophy (LD) and fat accumulation with another group of HIV-infected men with lipodystrophy but without fat accumulation. The patients suffering from LD may have high levels of IL-18 that may be closely associated with limb atrophy.

Author: Pedersen, Bente Klarlund, Gerstoft, Jan, Lindegaard, Birgitte, Hansen, Ann-Brit Eg
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
Influence, Lipodystrophy, Interleukin-18

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: Efficiency related to active case finding

Article Abstract:

Scaling up access to highly active antiretroviral therapy (HAART) requires eligibility criteria that safeguard treatment efficiency in resourse-poor settings. It is determined whether supply of HAART on the basis of plasma viral load testing could result in a stronger reduction of AIDS incidence as compared with CD4 count-driven strategies.

Author: Bossuyt, Patrick M.M., Zwinderman, Aeilko H., ogaards, JohannesA., Weverling, Gerrit Jan, Gaudsmit, Jaap
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
Drug therapy, Highly active antiretroviral therapy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, HIV infection, HIV infections, United States, Diagnosis
Similar abstracts:
  • Abstracts: Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke
  • Abstracts: Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults
  • Abstracts: Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial
  • Abstracts: Fracture resistance of roots endodontically treated with a new resin filling material. A review of the management of endodontically treated teeth
  • Abstracts: Naturally occurring immunomodulation: SIV infection in sooty mangabeys. Simian immunodeficiency virus infection of hematopoietic stem cells and bone marrow stromal cells
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.